Centre National De La Recherche Scientifique

Universiteit Gent

Vib Vzw

Centre Hospitalier Régional Universitaire De Montpellier

Universität Osnabrück

Universitè De Montpellier

Universite Montpellier 2

Universite Montepellier 2

Gilles Uzé

Jan Tavernier

Lennart Zabeau

Frank Peelman

Franciane Paul

Jennyfer Bultinck

Sarah Gerlo

Yann Bordat

Guillaume Cartron

Jacob Piehler

Geneviève Garcin

This disclosure relates to a modified &#x3b1;-helical bundle cytokine, with reduced activity via an &#x3b1;-helical bundle cytokine receptor, wherein the &#x3b1;-helical bundle cytokine is specifically delivered to target cells. Preferably, the &#x3b1;-helical bundle cytokine is a mutant, more preferably it is a mutant interferon, with low affinity to the interferon receptor, wherein the mutant interferon is specifically delivered to target cells. The targeting is realized by fusion of the modified &#x3b1;-helical bundle cytokine to a targeting moiety, preferably an antibody. This disclosure relates further to the use of such targeted modified &#x3b1;-helical bundle cytokine to treat diseases. A preferred embodiment is the use of a targeted mutant interferon, to treat diseases, preferably viral diseases and tumors.

Targeted and mutated human-interferon fusion proteins

Targeted human-interferon fusion proteins

Growing community of inventors

Montpellier, France

Gilles Uzé